Background:The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers.Methods:Using a previously reported cohort, we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease.Results:We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy.Conclusions:MRE11 has no predictive value in the analysis of relapse-free survival after chemo-radiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour-infiltrating lymphocyte scores. Further investigation into the role of DNA repair proteins in anal cancer is required.
Bibliographical noteFunding Information:
1CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK; 2Nuffield Department of Population Health, University of Oxford, Oxford OX3 7DQ, UK; 3Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Oxford OX3 7DQ, UK; 4Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 7DU, UK and 5Sussex Cancer Centre, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK
We thank Marcus Green for his expert technical assistance with block sectioning. This work was funded by CRUK Programme Grant C5255/A15935 (to AEK) and an MRC studentship to AKW (MR/K501256/1).
© 2017 Cancer Research UK.